Astellas and Theravance Report Additional Telavancin Data at 47th An...(fections) studies and represent the larg...)

Date:9/18/2007

fections) studies and represent the largest subset of surgical-site-associated cSSSIs from controlled clinical trials. In these studies, investigators compared clinical and microbiological responses from treatment with telavancin and vancomycin. In this subset, clinical cure, bacterial eradication and overall response rates were typically higher for telavancin.

Staphylococcus aureus is a common cause of surgical-site infections. Physicians report an increased proportion of these infections due to MRSA, a serious, potentially life-threatening infection that is becoming increasingly resistant to current treatments.

"Surgical site infections are a significant cause of death following surgery, and while vancomycin is a mainstay for treatment of these infections caused by MRSA, its decreasing effectiveness highlights the need for new antibiotics," said Samuel E. Wilson, MD, Professor of Surgery, University of California Irvine School of Medicine. "We are hopeful that telavancin will be a safe and useful treatment for serious and life-threatening complicated skin and skin structure infections."

Multiple Studies Support Telavancin

In addition to the analysis of a subset of patients with surgical site infections, 13 other telavancin abstracts were accepted at this year's ICAAC meeting. These data from multiple studies, taken in their entirety, provide insight into the potential benefits of telavancin. Abstracts included:

-- Comparative Use of Telavancin and Daptomycin Against MRSA in the

Neutropenic Murine Thigh Model

In this study, mice thigh tissue was injected with MRSA and dosed with

telavancin or daptomycin three or eight hours later. At three hours

following MRSA injection, reduction in bacteria concentrations were

comparable between the two treatments. However, at eight hours,

telavancin reduced bacteria concentrations to a greater degree than

daptomycin.

--
'/>"/>

SOURCE Astellas Pharma US, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
3. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
4. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
5. Versatile Reporter Vectors for Monitoring Viral Transduction
6. In Vivo Signal Transduction Pathway Reporting Systems
7. Improved Vectors for PathDetect Trans-Reporting Systems
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. Cis-Reporting System Monitors Intracellular Calcium Mobilization
10. Cis-Reporting System Monitors Intracellular Calcium Mobilization
11. PatchMan - Test Report